Daniel R Barnes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4206469/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Risks of Breast, Ovarian, and Contralateral Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. JAMA - Journal of the American Medical Association, 2017, 317, 2402.	7.4	1,898
2	A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nature Genetics, 2012, 44, 659-669.	21.4	762
3	Common Variants at 10 Genomic Loci Influence Hemoglobin A1C Levels via Glycemic and Nonglycemic Pathways. Diabetes, 2010, 59, 3229-3239.	0.6	387
4	Genome-Wide Association Identifies Nine Common Variants Associated With Fasting Proinsulin Levels and Provides New Insights Into the Pathophysiology of Type 2 Diabetes. Diabetes, 2011, 60, 2624-2634.	0.6	335
5	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	21.4	289
6	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 2020, 52, 572-581.	21.4	265
7	Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension. Nature Genetics, 2016, 48, 1151-1161.	21.4	261
8	Fifteen new risk loci for coronary artery disease highlight arterial-wall-specific mechanisms. Nature Genetics, 2017, 49, 1113-1119.	21.4	260
9	Functional Variants at the 11q13 Risk Locus for Breast Cancer Regulate Cyclin D1 Expression through Long-Range Enhancers. American Journal of Human Genetics, 2013, 92, 489-503.	6.2	201
10	Exome Sequencing Identifies Rare Deleterious Mutations in DNA Repair Genes FANCC and BLM as Potential Breast Cancer Susceptibility Alleles. PLoS Genetics, 2012, 8, e1002894.	3.5	186
11	Tumour risks and genotype–phenotype correlations associated with germline variants in succinate dehydrogenase subunit genes <i>SDHB</i> , <i>SDHC</i> and <i>SDHD</i> . Journal of Medical Genetics, 2018, 55, 384-394.	3.2	177
12	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	21.4	120
13	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications, 2019, 10, 1741.	12.8	90
14	No evidence for a causal link between uric acid and type 2 diabetes: a Mendelian randomisation approach. Diabetologia, 2011, 54, 2561-2569.	6.3	89
15	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	12.8	88
16	Meta-analysis of up to 622,409 individuals identifies 40 novel smoking behaviour associated genetic loci. Molecular Psychiatry, 2020, 25, 2392-2409.	7.9	83
17	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genetics in Medicine, 2020, 22, 1653-1666.	2.4	82
18	Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer. EBioMedicine, 2016, 10, 150-163.	6.1	69

DANIEL R BARNES

#	Article	IF	CITATIONS
19	Exome Chip Meta-analysis Fine Maps Causal Variants and Elucidates the Genetic Architecture of Rare Coding Variants in Smoking and AlcoholÂUse. Biological Psychiatry, 2019, 85, 946-955.	1.3	69
20	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Research, 2018, 78, 5419-5430.	0.9	54
21	Characterization of the Cancer Spectrum in Men With Germline <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variants. JAMA Oncology, 2020, 6, 1218.	7.1	48
22	Unravelling modifiers of breast and ovarian cancer risk for <i>BRCA1</i> and <i>BRCA2</i> mutation carriers: update on genetic modifiers. Journal of Internal Medicine, 2012, 271, 331-343.	6.0	47
23	The rs2910164:G>C SNP in the MIR146A gene is not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Human Mutation, 2011, 32, 1004-1007.	2.5	39
24	Association of Genomic Domains in <i>BRCA1</i> and <i>BRCA2</i> with Prostate Cancer Risk and Aggressiveness. Cancer Research, 2020, 80, 624-638.	0.9	39
25	RNF168 regulates R-loop resolution and genomic stability in BRCA1/2-deficient tumors. Journal of Clinical Investigation, 2021, 131, .	8.2	38
26	Evaluation of Association Methods for Analysing Modifiers of Disease Risk in Carriers of Highâ€Risk Mutations. Genetic Epidemiology, 2012, 36, 274-291.	1.3	37
27	Transcriptomeâ€wide association study of breast cancer risk by estrogenâ€receptor status. Genetic Epidemiology, 2020, 44, 442-468.	1.3	32
28	Impact of Common Variation in Bone-Related Genes on Type 2 Diabetes and Related Traits. Diabetes, 2012, 61, 2176-2186.	0.6	31
29	The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. Npj Breast Cancer, 2019, 5, 38.	5.2	28
30	Chromatin interactome mapping at 139 independent breast cancer risk signals. Genome Biology, 2020, 21, 8.	8.8	27
31	No Interactions Between Previously Associated 2-Hour Glucose Gene Variants and Physical Activity or BMI on 2-Hour Glucose Levels. Diabetes, 2012, 61, 1291-1296.	0.6	23
32	Exome array analysis identifies ETFB as a novel susceptibility gene for anthracycline-induced cardiotoxicity in cancer patients. Breast Cancer Research and Treatment, 2018, 167, 249-256.	2.5	23
33	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362.	2.8	23
34	Exome array analysis identifies GPR35 as a novel susceptibility gene for anthracycline-induced cardiotoxicity in childhood cancer. Pharmacogenetics and Genomics, 2017, 27, 445-453.	1.5	22
35	Non-coding RNAs underlie genetic predisposition to breast cancer. Genome Biology, 2020, 21, 7.	8.8	21
36	Attenuated familial adenomatous polyposis manifests as autosomal dominant late-onset colorectal cancer. European Journal of Human Genetics, 2014, 22, 1330-1333.	2.8	20

DANIEL R BARNES

#	Article	IF	CITATIONS
37	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nature Communications, 2021, 12, 1078.	12.8	19
38	Breast and Prostate Cancer Risks for Male <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variant Carriers Using Polygenic Risk Scores. Journal of the National Cancer Institute, 2022, 114, 109-122.	6.3	19
39	The predictive ability of the 313 variant–based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. Genetics in Medicine, 2021, 23, 1726-1737.	2.4	16
40	Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study. Genetics in Medicine, 2018, 20, 1575-1582.	2.4	15
41	Prediction of measured weight from selfâ€reported weight was not improved after stratification by body mass index. Obesity, 2013, 21, E137-42.	3.0	13
42	Epidemiology of ATTRV30M neuropathy in Cyprus and the modifier effect of complement C1q on the age of disease onset. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 220-226.	3.0	12
43	Altered regulation of <i>BRCA1</i> exon 11 splicing is associated with breast cancer risk in carriers of <i>BRCA1</i> pathogenic variants. Human Mutation, 2021, 42, 1488-1502.	2.5	7
44	Immune Cell Associations with Cancer Risk. IScience, 2020, 23, 101296.	4.1	6
45	Candidate Causal Variants at the 8p12 Breast Cancer Risk Locus Regulate DUSP4. Cancers, 2020, 12, 170.	3.7	6
46	Risk of breast or ovarian cancer in family members who do not carry the BRCA1 or BRCA2 family mutation: Findings from the EMBRACE study Journal of Clinical Oncology, 2017, 35, 1558-1558.	1.6	0